Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients

Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients Overview Company: Pulmonx Corporation Indication: Chronic Obstructive Pulmonary Disease (COPD)/Emphysema Drug: AeriSeal® System followed by Zephyr® Valves Trial Phase: N/A NCT ID: NCT06035120 Trial Initiation Details Pulmonx Corporation, a glob..